 Based on the ABSORB EXTEND trial there are some suggestions for longer dual antiplatelet therapy duration and more potent agents than clopidogrel i.e. ticagrelor regardless of clinical presentation, particularly in the first months after BVS implantation. Ticagrelor in the PLATO trial has been shown to reduce the rate of a combined endpoint of cardio-vascular death, myocardial infarction, or stroke compared to clopidogrel. In patients treated with PCI, it also reduces the rate of stent thrombosis. Statins are the most widely used LDL-lowering drugs in high-risk patients. It is recommended to achieve a greater than 50 reduction in LDL levels. Treatment goal for fasting LDL-cholesterol is 70 mgdl 1.8 mmoll. In comparison with other lipid-lowering agents, rosuvastatin is the most potent agent to achieve the required reduction of LDL. Rosuvastatin in maximal tolerated dose is indicated to reduce the risk of myocardial infarction and revascularization procedures. 